Free Republic
Browse · Search
General/Chat
Topics · Post Article

Skip to comments.

Q ~ Trust Trump's Plan ~ 08/18/21 Vol.365, Q Day 1391
qalerts.net ^ | 08/18/21 | FReeQs, FReepers, and vanity

Posted on 08/18/2021 6:10:32 PM PDT by ransomnote

Joe Biden's State Dept Halted a Trump-Era 'Crisis Response' Plan Aimed at Avoiding Benghazi-Style Evacuations Just MONTHS Before Taliban Takeover. 


Q is the result of the sacrifices and commitment of countless patriots to win back our captured country from the Deep State and achieve the transformation President Trump promised in this campaign video. President Trump has said the awakening of the public is key to this transformation.

Q describes this awakening as follows: 

"The Great Awakening ('Freedom of Thought’), was designed and created not only as a backchannel to the public (away from the longstanding 'mind’ control of the corrupt & heavily biased media) to endure future events through transparency and regeneration of individual thought (breaking the chains of ‘group-think’), but, more importantly, aid in the construction of a vehicle (a ‘ship’) that provides the scattered (‘free thinkers’) with a ‘starter’ new social-networking platform which allows for freedom of thought, expression, and patriotism or national pride (the feeling of love, devotion and sense of attachment to a homeland and alliance with other citizens who share the same sentiment).

When ‘non-dogmatic’ information becomes FREE & TRANSPARENT it becomes a threat to those who attempt to control the narrative and/or the stable. 

When you are awake, you stand on the outside of the stable (‘group-think’ collective), and have ‘free thought’. 

"Free thought" is a philosophical viewpoint which holds that positions regarding truth should be formed on the basis of logic, reason, and empiricism, rather than authority, tradition, revelation, or dogma. 

When you are awake, you are able to clearly see. 

The choice is yours, and yours alone. 

Trust and put faith in yourself. 

You are not alone and you are not in the minority. 

Difficult truths will soon see the light of day. 

WWG1WGA!!!" ~ Q (#3038)

The video, Qanon is 100% coming from the Trump Administration, is just one of many excellent responses to the all-important question, "Whom does Q serve?"

Q Boot Camp is a quick, condensed way to learn the background and basics about the Q movement. 

Q has reminded us repeatedly that together, we are strong. As the false "narrative" is destroyed and the divisive machinery put in place by the Deep State fails, the fact that patriotism has no skin color or political party is exposed for all to see. 

In the battle between those who strip us our constitutional rights, we can't afford to let false divisions separate us any longer. We, and our country, will be forever made stronger by diligently seeking the truth, independence and freedom of thought.

Where We Go 1, We Go All





TOPICS: Conspiracy; Miscellaneous; Weird Stuff
KEYWORDS: alrightqnowwhat; alternatereality; anydaynow; believeanythingcrowd; cmongodqletmedownnow; delusional; dontletmedownnowq; givemeqorgivemedeath; ibelieveinqamialoser; ilovemakebelieveland; imaginaryworld; imdoneresearching; imgulliblesoqlovesme; imstillhangingonq; ingoditrustbutnotq; ivebeenhadbyq; ivehadenoughofqnow; mandoesthisplansuck; mentalillness; noexecutionsqyousuck; planlolwhatplan; ptbarnumwasrightlol; q; qdontlietomeillbemad; qenoughisenoughbye; qisforrealormaybenot; qisthetruthithink; qtards; qtellmeimnotnuts; qtellmewhattobelieve; qtownguyana; saintmikelindell; scientologyday25185; sofakingretoaded; stillnoexecutionsyet; thereisnoplannowwhat; trustliars; trustnutcases; trustretards; trusttheinsane; trusttraitors; whenqisdonewhatsnext; wherearemyarrestsnow
Navigation: use the links below to view more comments.
first previous 1-20 ... 2,121-2,1402,141-2,1602,161-2,1802,181-2,189 last
To: thinden; C210N

And a little after the 43 m mark (when the crowd reacts to the infamous riff on “woke”), the guy holds up the 17 sign also.


2,181 posted on 08/24/2021 8:28:52 PM PDT by 17strings (There are 2 means of refuge from the miseries of life, music & cats. - A. Schweitzer)
[ Post Reply | Private Reply | To 2180 | View Replies]

Bkmk
Interesting


2,182 posted on 08/26/2021 6:34:02 AM PDT by AllAmericanGirl44 (“The truth does not change according to our ability to stomach it”)
[ Post Reply | Private Reply | To 1737 | View Replies]

To: Tennessee Conservative

The amount per dose is the same for prevention as for infection; what differs is the frequency.


2,183 posted on 08/30/2021 5:35:44 AM PDT by grey_whiskers (The opinions are solely those of the author and are subject to change with out notice.)
[ Post Reply | Private Reply | To 1173 | View Replies]

To: grey_whiskers

I was doing the prevention one day a week but I read the frequency for infection is one dose 5-7 days a week. I’m glad it’s the same size dose though. That would make it much easier.


2,184 posted on 08/30/2021 5:38:37 AM PDT by Tennessee Conservative (My goal in life is to be the person my dog's think I am)
[ Post Reply | Private Reply | To 2183 | View Replies]

To: Tennessee Conservative

That’s pretty much what I read too; I think one source uses only once a month for prevention...?


2,185 posted on 08/30/2021 5:48:51 AM PDT by grey_whiskers (The opinions are solely those of the author and are subject to change with out notice.)
[ Post Reply | Private Reply | To 2184 | View Replies]

New Microbes New Infect. 2021 Sep; 43: 100924.
Published online 2021 Aug 3. doi: 10.1016/j.nmni.2021.100924
PMCID: PMC8383101
PMID: 34466270

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19

Abstract

In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world’s most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

Keywords: COVID-19, H. pylori, ivermectin, SARS-CoV-2, spike protein

Introduction

The 2015 Nobel prize for the discovery of ivermectin (IVM) and an antimalarial treatment was the Nobel committee’s first award for treatment agents for infectious diseases since the one in 1952 for streptomycin [1]. A macrocyclic lactone of multifaceted potency [2,3], IVM as deployed worldwide since 1987 has made major inroads against two devastating tropical diseases, onchocerciasis and lymphatic filariasis [4]. During the year since IVM treatment was first applied to COVID-19, another global scourge [5], results from more than 20 randomized clinical trials (RCTs) of IVM treatment of COVID-19 have been reported [2,6,7], with inpatient and outpatient treatments of COVID-19 conducted in 25 countries [2]. A likely biological mechanism has been indicated to be competitive binding with SARS-CoV-2 spike protein sites, as reviewed [8,9].

Recently, Dr Satoshi Omura, the Nobel co-laureate for the discovery of IVM, and colleagues conducted a comprehensive review of IVM clinical activity against COVID-19, concluding that the preponderance of the evidence demonstrated major reductions in mortality and morbidity [2]. Our review of that evidence, updated with consideration of several new studies, supports the same conclusion.

Animal studies for IVM treatment of SARS-CoV-2 and a closely related betacoronavirus

A framework for the examination of clinical IVM treatment results for COVID-19 is provided by related animal studies using IVM at low human-equivalent doses. In golden hamsters that were intranasally inoculated with SARS-CoV-2, causing symptomatic COVID-19 infections, concurrent dosing with IVM significantly reduced the severity of clinical signs (p < 0.001). While viral load was not reduced, these improvements included one-third of the incidence of anosmia and sharp reductions in the Il-6/Il-10 ratio in lung tissue [10]. In another animal model, mice were infected with mouse hepatitis virus MHV-A59 [11], a betacoronavirus strain that does not express hemagglutinin esterase [12], like SARS-CoV-2, SARS-CoV, and MERS [8]. Whereas infected mice had severe histopathological liver damage, IVM-treated mice had half the hepatic viral load and minimal liver damage, not significantly different than that observed in uninfected controls.

RCTs for IVM treatment and prevention of COVID-19

More than 20 RCTs for IVM treatment of COVID-19 have been conducted to date, as cited above. A search of Google Scholar for meta-analyses of IVM treatment studies of COVID-19 that appeared in 2021 [13] yielded seven such studies that drew conclusions from RCTs only [6,[14][15][16][17][18][19]]. The relative risk (RR) of mortality with IVM treatment vs. controls as calculated in four of these meta-analyses using Cochrane analysis methodology ranged from 0.25 to 0.37, with a mean of 0.31 [6,14,15,19]. The three other meta-analyses reported odds ratios of 0.16, 0.21 and 0.33, with a mean of 0.23 [[16][17][18]]. Six of these seven meta-analyses concluded that there was a significant [6,[14][15][16]] or possible [17,18] indication of the efficacy of IVM in reducing COVID-19 mortality. One found no evidence of IVM efficacy in its first version [20], reporting an RR of 1.11 for IVM treatment vs. controls, and stuck with that finding even after changing this RR value to 0.37 and correcting switched treatment and control deaths it had misreported for one study [21] in a revised version [19]. Among the most recent and comprehensive of these seven meta-analyses reported a pooled total of 31 deaths among 1101 subjects in IVM treatment groups and 91 deaths among 1064 controls from 11 RCTs, amounting to a 67% reduction in mortality, with a statistical significance for an overall effect of p = 0.005 [16]. The RCT that used the largest dose of IVM, 400 μg/kg on each of days 1-4 [22], had 2 vs. 24 deaths in the treatment vs. control groups (n = 200 each).

An objection that had been raised earlier in 2021 to the preponderance of clinical evidence for the efficacy of IVM treatment of COVID-19 as summarized above was that none of these RCTs had been published in mainstream peer-reviewed scientific journals [23]. Closing that gap, however, was the publication in 2021 in journals from major scientific publishers of five such RCTs for COVID-19 treatment [[24][25][26][27][28]], each showing multiple clinical benefits for IVM vs. controls, most of these to statistical significance at p < 0.002. Also published in 2021 were three other RCTs for IVM treatment of COVID-19: one that reported briefer hospital stays for IVM treatment short of statistical significance (p = 0.08) [29], another that compared IVM with two other drug treatment groups but not a placebo group and found no benefit [30], and an additional study conducted in Cali, Columbia with mix-ups between treatment and placebo doses as described below.

Another objection that has been raised to the RCT evidence supporting IVM efficacy was that study populations were too small [31]. Yet, it is well known in clinical trial design that highly effective drugs will establish statistically significant results with smaller sample sizes, with larger study populations required for minimally effective drugs [32,33]. But for a drug with a more modest RR of 75%, for example, the treatment and control arms would need more than 3800 subjects each to yield the same statistical significance [33]. Although large study populations are useful to screen for adverse effects (AEs) of new drugs, IVM has been used safely in 3.7 billion doses worldwide since 1987 [2,3] and is well tolerated even at much greater doses than the standard single dose of 200 μg/kg [34,35]. It has been used in RCTs for COVID-19 treatment at cumulative doses of 1500 μg/kg [36], 1600 μg/kg [22] and 3000 μg/kg [37] over 4 or 5 days with only small percentages of mild or transient adverse effects.

Among these RCTs that established safety for high-dose IVM treatment of COVID-19 was one conducted in Cali, Columbia, with generally mild COVID-19 cases, median age 37, having only one death in the control group [36]. The study found no statistically significant symptom improvements with IVM treatment yet reported a striking anomaly: AEs distinctive for its high IVM dose, described in the study protocol as ‘security parameters’ for its IVM use, occurred at almost identical rates in its IVM and placebo arms. These included transient incidences of blurred vision (11.3%, 11.6%) and dizziness (35.6%, 34.3%). These indications of IVM use in controls occurred as over-the-counter sales of IVM surged in the study region during the study period (Supplementary Table 1). Further questions as to the study’s treatment/control boundaries were raised by the mistaken substitution of IVM for placebo for 38 patients, discovered by the lead pharmacist a month after the fact (study, p. 3; study protocol supplement, p. 43). In addition, blinding was breached by the use of the dextrose-saline solution as the placebo for 64 control patients (IVM tastes distinctively bitter), while the composition of the replacement placebo solution was not specified [38].

Supporting the findings of IVM efficacy in COVID-19 treatment as summarized above were indications of activity against SARS-CoV-2 in prevention studies. Three RCTs evaluated the prophylactic effect of IVM administered to cohorts of 100 [22], 117 [39] and 203 [40] subjects exposed to COVID-19 patients. These studies, all using IVM in doses of at least 150 μg/kg per week, reported statistically significant reductions in COVID-19 incidences, with respective RRs of 20%, 26% and 13% as compared with controls, and greater reductions in incidences of moderate and severe cases. Another RCT for COVID-19 prevention administered just one dose of IVM at 12 mg (about 150 μg/kg) to 617 subjects on day one of a 42-day observation period, while three other preventative regimens were each administered daily over that period [41]. IVM at that single low dose yielded the best results of these four regimens, with highly statistically significant reductions of close to 50% in both symptomatic COVID-19 and acute respiratory symptoms vs. controls.

14-fold reductions in excess deaths with IVM use in Peru, then 13-fold increase after IVM restricted

The clinical experience of IVM treatments of COVID-19 in 25 countries extends far beyond the RCT results summarized, yet incomplete tracking and lack of control data exclude most of this for evaluation. The record of nationally authorized such treatments in Peru provides a notable exception [42]. In ten states of Peru, mass IVM treatments of COVID-19 were conducted through a broadside, army-led effort, Mega-Operación Tayta (MOT), that began on different dates in each state. In these MOT states, excess deaths dropped sharply over 30 days from peak deaths by a mean of 74%, in close time conjunction with MOT start date (Fig. 1B). In 14 states of Peru having locally administered IVM distributions, the mean reduction in excess deaths over 30 days from peak deaths was 53%, while in Lima, which had minimal IVM distributions during the first wave of the pandemic due to restrictive government policies there, the corresponding 30-day decrease in excess deaths was 25%.

 

A) Excess all-cause deaths (all ages), the national population of Peru. These decreased 14-fold from 1st August through 1st December 2020; then, after IVM use was restricted, increased 13-fold through 1st February. For A and B, y values are 7-day moving averages; for B and C, ages ≥60. Data are from Peru’s National Death Information System (SINADEF). (B) Drops in excess deaths for all states of operation MOT, an army-led program of mass IVM distributions, but Pasco, which had them on three dates. • MOT start date; ▴ peak deaths; ▪ day of peak deaths +30 days. Junin distributed IVM through local channels 13 days before MOT start. (C) Reductions in excess deaths at +30 days after peak deaths for the 25 states by extent of IVM distributions: maximal-MOT (Image 1), mean -74%; moderate-local distributions (Image 2), mean -53%; and minimal-Lima (Image 3), -25%. The absolute value of these reductions by state correlated with extent of IVM distributions with Kendall τb = 0.524, p < 0.002 (Spearman rho = 0.619, p < 0.001). All these data are from publicly accessible Peruvian national databases, with associated frozen datasets available from the Dryad data repository [42].

Reductions in excess deaths by state (absolute values) correlated with the extent of IVM distribution (maximal-MOT states, moderate-local distributions, and minimal-Lima) with Kendall τb = 0.524, p < 0.002, as shown in Fig. 1C. Nationwide, excess deaths decreased 14-fold over four months through 1st December 2020. After a restrictive IVM treatment policy was enacted under a new Peruvian president who took office on 17th November, however, deaths increased 13-fold over the two months following 1st December through 1st February 2021 (Fig. 1A). Potential confounding factors, including lockdowns and herd immunity, were ruled out using Google community mobility data, seropositivity rates, population densities and geographic distributions of SARS-CoV-2 genetic variations and by restricting all analysis except that for Fig. 1A to ages ≥ 60. Excess deaths were used in all analyses rather than COVID-19 case fatalities as gross underreporting of pandemic deaths by case fatalities was known to the Peruvian Ministry of Health since July 2020 [43]. This disparity has been consistently manifested in the national health database figures for COVID-19 case fatalities vs. all natural-cause deaths since that date [42].

IVM-based combination treatments and other research in progress

Combination treatments using IVM and adjuncts have shown indications of efficacy against COVID-19 in RCTs conducted to date [24,44]. Results using IVM, doxycycline and zinc to treat serious and critical cases having spO2 ≤ 90 prior to treatment, with spO2 changes tracked 24 hours after treatment, will be reported by TJB with Sabine Hazan, MD. Pronounced improvements of serious COVID-19 symptoms within 1–2 days after IVM administration have been observed in several patients treated by the lead author (ADS), and studies to objectively track such short-term clinical benefits of IVM for COVID-19 are underway. Information on other combination treatments using IVM with agents such as fluvoxamine, for which clinical studies also indicate significant benefits [45], is provided by the USA-based FLCCC alliance (https://covid19criticalcare.com).

The curative potential of combination therapy was demonstrated in a medical breakthrough of three decades prior for another disease, peptic ulcers, for which the discovery of its underlying bacterial cause, Helicobacter pylori, was honoured with the Nobel Prize for Medicine in 2005. In 1990, Dr Thomas J. Borody published the original clinical trial of a combination treatment for H. pylori, achieving a 96% cure rate for a triple therapy consisting of three repurposed drugs, bismuth subcitrate and two antibiotics [46]. Between 1990 and 2015, an estimated 18,665 deaths were prevented by the timely application of this triple therapy for peptic ulcer disease in Australia [47]. After the expiration of the patents for two palliative drugs for this condition, Tagamet and Zantac [48], which had each earned billions of dollars, triple therapy became the standard of care for peptic ulcers in the rest of the world by the late 1990s.

Conclusion

We believe that the evidence to date supports the worldwide extension of IVM treatments for COVID-19, complementary to immunizations. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, as reviewed [8], possibly yielding full efficacy against emerging viral mutant strains. IVM has been safely used in 3.7 billion doses since 1987, well tolerated even at much greater than standard doses [34,35] and used without serious AEs in the three high-dose COVID-19 treatment studies noted above [34,36,37]. In the current international emergency of COVID-19, with mutant viral strains, vaccination refusals and potentially waning immunities over months presenting new challenges, IVM can be an effective component of the mix of therapeutics deployed against this pandemic.

Funding

No funding was received for this perspective.

Ethical approval and consent to participate

This is a review and ethical approval was not required.

Transparency declaration

TJB is a principal in Topelia Therapeutics (Ventura, California), which seeks to commercialize cost-effective treatments for COVID-19, including IVM. All other authors report no conflicts of interest.

Footnotes

Appendix ASupplementary data to this article can be found online at https://doi.org/10.1016/j.nmni.2021.100924.

Appendix A. Supplementary data

The following is/are the supplementary data to this article:

Multimedia component 1:
Click here to view.(326K, pdf)Multimedia component 1

 

References

1. Ergonul O., Yalcin C.E., Erkent M.A., Demirci M., Uysal S.P., Ay N.Z. Who can get the next Nobel Prize in infectious diseases? Int J Infect Dis. 2016;45:88–91. [PubMed[Google Scholar]
2. Yagisawa M., Foster P.J., Hanaki H., Omura S. Global trends in clinical studies of ivermectin in COVID-19. Japanes J Antib. 2021;74(1) [Google Scholar]
3. Campbell W.C. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. Curr Pharm Biotechnol. 2012;13(6):853–865. [PubMed[Google Scholar]
4. Crump A., Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(2):13–28. [PMC free article] [PubMed[Google Scholar]
5. Rajter J.C., Sherman M.S., Fatteh N., Vogel F., Sacks J., Rajter J.-J. Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19 (ICON study) CHEST. 2020 doi: 10.1016/j.chest.2020.10.009. [PMC free article] [PubMed] [CrossRef[Google Scholar]
6. Hill A., Abdulamir A., Ahmed S., Asghar A., Babalola O.E., Basri R. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Res Square. 2021 doi: 10.21203/rs.3.rs-148845/v1. [CrossRef[Google Scholar]
7. Kory P., Gu Meduri, Varon J., Iglesias J., Marik P.E. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Therap. 2021;28(3):e299–e318. [PMC free article] [PubMed[Google Scholar]
8. Scheim D.E. 2020. From cold to killer: how SARS-CoV-2 evolved without hemagglutinin esterase to agglutinate, then clot blood cells in pulmonary and systemic microvasculature SSRN.http://ssrn.com/abstract=3706347 Available from: [Google Scholar]
9. Zaidi A.K., Dehgani-Mobaraki P. The mechanisms of action of Ivermectin against SARS-CoV-2: an evidence-based clinical review article. J Antib. 2021 doi: 10.1038/s41429-021-00430-5. [PMC free article] [PubMed] [CrossRef[Google Scholar]
10. Melo G.D., Lazarini F., Larrous F., Feige L., Kergoat L., Marchio A. Anti-COVID-19 efficacy of ivermectin in the golden hamster. bioRxiv. 2020 doi: 10.1101/2020.11.21.392639. [CrossRef[Google Scholar]
11. Arévalo A.P., Pagotto R., Pórfido J.L., Daghero H., Segovia M., Yamasaki K. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Scient Reports. 2021;11(1):7132. [PMC free article] [PubMed[Google Scholar]
12. Kazi L., Lissenberg A., Watson R., de Groot R.J., Weiss S.R. Expression of hemagglutinin esterase protein from recombinant mouse hepatitis virus enhances neurovirulence. J Virol. 2005;79(24):15064–15073. [PMC free article] [PubMed[Google Scholar]
13. Search for papers having "ivermectin," "meta," and "COVID" OR "SARS" in the title, appearing in 2021. https://scholar.google.com/scholar?as_q=ivermectin+meta+%28COVID+OR+SARS%29&as_epq=&as_oq=&as_eq=&as_occt=title&as_sauthors=&as_publication=&as_ylo=2021&as_yhi=2021&hl=en&as_sdt=0%2C47 Available from:
14. Bryant A., Lawrie T.A., Dowswell T., Fordham E.J., Mitchell S., Hill S.R. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Amer J Therap. 2021 doi: 10.1097/MJT.0000000000001402. [PMC free article] [PubMed] [CrossRef[Google Scholar]
15. Hariyanto T.I., Halim D.A., Rosalind J., Gunawan C., Kurniawan A. Ivermectin and outcomes from Covid-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies. Rev Med Virol. 2021 doi: 10.1002/rmv.2265:e2265. [CrossRef[Google Scholar]
16. Karale S., Bansal V., Makadia J., Tayyeb M., Khan H., Ghanta S.S. A meta-analysis of mortality, need for ICU admission, use of mechanical ventilation and adverse effects with ivermectin use in COVID-19 patients. medRxiv. 2021 doi: 10.1101/2021.04.30.21256415. [CrossRef[Google Scholar]
17. Kow C.S., Merchant H.A., Mustafa Z.U., Hasan S.S. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Reports. 2021 doi: 10.1007/s43440-021-00245-z. [PMC free article] [PubMed] [CrossRef[Google Scholar]
18. Rodríguez-Gutiérrez R., Raygoza-Cortez K., Garcia-Leal M., Sáenz-Flores M., Solis R.C., Flores-Rodríguez A. 2021. Ivermectin in the prophylaxis and treatment of patients with SARS-CoV-2: a living systematic review and meta-analysis SSRN.http://ssrn.com/abstract=3802499 Available from: [Google Scholar]
19. Roman Y.M., Burela P.A., Pasupuleti V., Piscoya A., Vidal J.E., Hernandez A.V. Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. medRxiv. 2021 doi: 10.1101/2021.05.21.21257595. [PMC free article] [PubMed] [CrossRef[Google Scholar]
20. Roman Y.M., Burela P.A., Pasupuleti V., Piscoya A., Vidal J.E., Hernandez A.V. Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials (version 1) medRxiv. 2021 doi: 10.1101/2021.05.21.21257595v1. [PMC free article] [PubMed] [CrossRef[Google Scholar]
21. Niaee M.S., Gheibi H., Namdar P., Allami A. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients; A randomized multi-center clinical trial. Res Square. 2020 doi: 10.21203/rs.3.rs-109670/v1. [CrossRef[Google Scholar]
22. Elgazzar A., Hany B., Abo Youssef S., Hany B. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Res Square. 2020 doi: 10.21203/rs.3.rs-100956/v1. [CrossRef[Google Scholar]
23. Sax P.E. Ivermectin for aaCOVID-19 — breakthrough treatment or hydroxychloroquine redux? NEJM J Watch. January 4, 2021 https://blogs.jwatch.org/hiv-id-observations/index.php/ivermectin-for-covid-19-breakthrough-treatment-or-hydroxychloroquine-redux/2021/01/04/] Available from: [Google Scholar]
24. Mahmud R., Rahman M.M., Alam I., Ahmed K.G.U., Kabir A.K.M.H., Sayeed S.K.J.B. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021;49(5) 03000605211013550. [PMC free article] [PubMed[Google Scholar]
25. Okumuş N., Demirtürk N., Çetinkaya R.A., Güner R., Avcı İ.Y., Orhan S. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis. 2021;21(1):411. [PMC free article] [PubMed[Google Scholar]
26. Samaha A.A., Mouawia H., Fawaz M., Hassan H., Salami A., Bazzal A.A. Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon. Viruses. 2021;13(6):989. [PMC free article] [PubMed[Google Scholar]
27. Shahbaznejad L., Davoudi A., Eslami G., Markowitz J.S., Navaeifar M.R., Hosseinzadeh F. Effect of ivermectin on COVID-19: a multicenter double-blind randomized controlled clinical trial. Clin Therap. 2021 doi: 10.1016/j.clinthera.2021.04.007. [PMC free article] [PubMed] [CrossRef[Google Scholar]
28. Chaccour C., Casellas A., Blanco-Di Matteo A., Pineda I., Fernandez-Montero A., Ruiz-Castillo P. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClin Med. 2021 doi: 10.1016/j.eclinm.2020.100720. [PMC free article] [PubMed] [CrossRef[Google Scholar]
29. Abd-Elsalam S., Noor R.A., Badawi R., Khalaf M., Esmail E.S., Soliman S. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study. J Med Virol. 2021 doi: 10.1002/jmv.27122. [PMC free article] [PubMed] [CrossRef[Google Scholar]
30. Galan L.E.B., Santos N.M.D., Asato M.S., Araújo J.V., de Lima Moreira A., Araújo A.M.M. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. Pathog Glob Heal. 2021;115(4):235–242. [PMC free article] [PubMed[Google Scholar]
31. COVID-19 scientific advisory group rapid evidence report: ivermectin in the treatment and prevention of COVID-19: alberta health services. February 2, 2021. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-ivermectin-in-treatment-and-prevention-rapid-review.pdf Available from: [Google Scholar]
32. Sakpal T.V. Sample size estimation in clinical trial. Persp Clin Res. 2010;1(2):67–69. [PMC free article] [PubMed[Google Scholar]
33. Kohn M., Senyak J. April 29, 2021. Sample size calculators: UCSF CTSI.https://www.sample-size.net/] Available from: [Google Scholar]
34. Navarro M., Camprubí D., Requena-Méndez A., Buonfrate D., Giorli G., Kamgno J. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020;75(4):827–834. [PubMed[Google Scholar]
35. Guzzo C.A., Furtek C.I., Porras A.G., Chen C., Tipping R., Clineschmidt C.M. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122–1133. [PubMed[Google Scholar]
36. López-Medina E., López P., Hurtado I.C., Dávalos D.M., Ramirez O., Martínez E. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021 doi: 10.1001/jama.2021.3071. [PMC free article] [PubMed] [CrossRef[Google Scholar]
37. Krolewiecki A., Lifschitz A., Moragas M., Travacio M., Valentini R., Alonso D.F. 2020. Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial: SSRN.http://ssrn.com/abstract=3714649 Available from: [Google Scholar]
38. Scheim D.E., Hibberd J.A., Chamie J.J. 2021. Protocol violations in López-Medina et al.: 38 switched ivermectin (IVM) and placebo doses, failure of blinding, ubiquitous IVM use OTC in Cali, and nearly identical AEs for the IVM and control groups: OSF Preprints. Available from: [CrossRef[Google Scholar]
39. Chahla R.E., Medina Ruiz L., Ortega E.S., Morales M.F., Barreiro F., George A. A randomized trial - intensive treatment based in ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in healthcare agents. medRxiv. 2021 doi: 10.1101/2021.03.26.21254398. [CrossRef[Google Scholar]
40. Shouman W., Hegazy A., Nafae R., Ragab M., Samra S., Ibrahim D. Use of ivermectin as a prophylactic option in asymptomatic family close contacts with patients of COVID-19 (NCT number: 04422561) J Clin Diagnos Res. 2021;15(2):OC27. [Google Scholar]
41. Seet R.C.S., Quek A.M.L., Ooi D.S.Q., Sengupta S., Lakshminarasappa S.R., Koo C.Y. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial. Int J Infect Dis. 2021;106:314–322. [PMC free article] [PubMed[Google Scholar]
42. Chamie J.J., Hibberd J.A., Scheim D.E. 2021. Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p<0.002 for effect by state, then 13-fold increase after ivermectin use restricted: OSF Preprints. Available from: Access date June 10, 2021. Associated frozen data from the Peruvian SINADEF database used in this analysis is available from the Dryad data repository at https://doi.org/10.5061/dryad.dv41ns1xr. [CrossRef[Google Scholar]
43. Covid-19: segundo informe para actualizar cifra de fallecidos se conocerá esta semana. Andina. Agencia Peruana de Noticias; 2020. 2020/07/26. [Google Scholar]
44. Hashim H.A., Maulood M.F., Rasheed A.M., Fatak D.F., Kabah K.K., Abdulamir A.S. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020 doi: 10.1101/2020.10.26.20219345. [CrossRef[Google Scholar]
45. Sukhatme V.P., Reiersen A.M., Vayttaden S.J., Sukhatme V.V. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12(763) [PMC free article] [PubMed[Google Scholar]
46. George L.L., Borody T.J., Andrews P., Devine M., Moore-Jones D., Walton M. Cure of duodenal ulcer after eradication of Helicobacter pyloriMed J Aust. 1990;153(3):145–149. [PubMed[Google Scholar]
47. Eslick G.D., Tilden D., Arora N., Torres M., Clancy R.L. Clinical and economic impact of "triple therapy" for Helicobacter pylori eradication on peptic ulcer disease in Australia. Helicobacter. 2020;25(6) [PubMed[Google Scholar]
48. Berndt E.R., Kyle M., Ling D. In: Scanner data and price indexes. Feenstra R.C., Shapiro M.D., editors. Univeristy of Chicago Press; Chicago: 2003. The long shadow of patent expiration: generic entry and rx-to-OTC switches; pp. 229–274. [Google Scholar]
 
 

2,186 posted on 09/06/2021 2:49:34 AM PDT by ransomnote (IN GOD WE TRUST)
[ Post Reply | Private Reply | To 2185 | View Replies]

To: ransomnote

forgot link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383101/


2,187 posted on 09/06/2021 2:51:05 AM PDT by ransomnote (IN GOD WE TRUST)
[ Post Reply | Private Reply | To 2186 | View Replies]

To: ransomnote
They Want to Arrest and Jail All Unvaccinated Adults! - YouTube

Mark Dice (introduction) As you know there's a growing

controversy about mandatory vaccinations

and i want to see if Americans are

willing to arrest those others who refuse to take

this coronavirus vaccine

violating the most fundamental rights of

one's personal liberty

 

Mark Dice: (to man walking by) You know a lot of people still haven't taken the vaccine with everything that's

going on so we're trying to mandate the vaccination


Man: Oh, no!

 

Mark Dice: we want to start arresting them if

they're not going to be taking that

 

Man: Are you kidding me?

 

Mark Dice: That's what the petition is for sir

 

Man: You know that's fascism man! (leaves)

 

Mark Dice: Real quick, we support mandating the

vaccine a lot of people still refusing

to take it and they're putting the rest

of us at risk so (next man begins to sign petition) we’re going to start mandating the vaccine

or start arresting these anti-vaxxers

if they're not going to follow the rules.

Birth Date,  and a Signature (to man signing.)

I don't want to hear any

of this ‘my body my choice’ stuff in today's New

World Order. We're gonna we're gonna put things right

 

Man: Absolutely, We all need that.

 

Mark Dice: Thank you.

 

Mark Dice: So we're gonna start having

them arrested if they refuse

 

Woman: I agree.

 

Mark Dice: Print , Birthday,

Signature (to woman signing the petition) to incarcerate the

anti-vaxxers i'm not sure what country

they think they're living in

 

Mark Dice: Some people are concerned about any

possible long-term side effects that

haven't shown up in studies yet but the time to

worry about that's in the future (to man and woman signing  the petition) so for now they can worry about that in jail if they refuse to take the vaccine (to woman signing petition)


Woman: I know. I don’t want to get close to anybody right now…

Mark Dice: it's time for some firm measures to take

care of these people and you know they can ....

Woman: I just can’t believe these people don’t get it. 

Mark Dice: Well it's time it's time to give them a

little incentive and

they can think about what they've done

sitting in jail until they're ready to

take the jab. thank you

 

Mark Dice:  Please sign the petition to

start arresting these anti-vaxxers that

haven't got the vaccine yet they're...


Man with surfboard: You want to

arrest people for not getting a vaccine?!

 

Mark Dice: They're contributing to the delta

variants being spread...

 

Man: You’re a scumbag, Dude. (leaves)

 

Mark Dice: Yeah just to mandate the vaccine for

everybody or (man and two women, man says “I am anti-anti vax”) to stop the anti-vaxxers it's time to

start arresting them if they

refuse and drastic times take

drastic measures to resolve these issues

so (first woman signing petition)

yeah the governor just mandated it for

all healthcare workers today


Second woman: Good!

 

Mark Dice: And so we're going to mandate it for

everybody or

they can sit in jail and think about

what they've done

 

Man: Yeah.

Woman (still signing): "Yeah the Delta variant is on them."

 

Mark Dice: Yeah the delta variant it's the primary

strain in many areas now

thank you very much

 

Mark Dice: you for your

concern for others (to someone off screen)

 

Mark Dice: We want to mandate the vaccine a lot of

these anti-vaxxers still refusing to get

vaccinated but we still need some more

signatures to make sure that we can

arrest them if they refuse

Man: Mandate?

Mark Dice: The vaccine we're going to force

them to take it. Yeah.


Mark Dice:  Print,

Birth Date, and a Signature (to man signing, who says “mandate?” again) you know

it's been long enough for them to make a

decision so we're going to make that decision

for them and if they refuse to take it

we're going to have them arrested. Thank

you for your support.

After man who just signed walks away, Mark Dice covers lower half of face with clipboard and laughs.

Mark Dice: Are you over 18?

One of two women walking together: "Yes"

Mark Dice: We support

mandating the vaccine. Governor Newsom

just mandated it today for all health

care workers but

still a lot of people refusing to take

it so we want to we want to

help encourage them by mandating it or

arrests like anti-vaxxers

 

One of two women reads the petition title aloud: “Arrest non-vaxxers?” and begins to sign the petition.

 

Mark Dice: Yeah we're going to have to put them

into you know safe centers to keep them

away from the rest of us

so Print Birthdate and a Signature.

You know desperate times call for

desperate measures

 

Mark Dice: (to another individual signing the petition) Well there's going to be some

criminal penalties for those who refuse

to take the vaccine and if

they're not going to make that decision

then we can put them

into jail and they can think about why

it is that they're

refusing and when they decide to take it

we can let them back out amongst the

rest of us

so thank you for supporting that.


Person who just signed asks: "Do you

really think that that will happen?"

 

Mark Dice: Well the vaccine passports are coming

and they're already in other countries where

you can't go to the store or to the

uh out to eat and they're coming here

and we'll be able to identify these

people

and if they refuse then we'll have them

arrested

 

Same woman who just signed:"Well, that's what i think should

happen."

Mark Dice: Support mandating the vaccine? (to two men) A lot of

these people still refusing to take the

vaccine and putting everyone else at

risk

One of two men shakes his head and says in disgust, “Yeah, right!”and moves past Dice saying, “I wouldn't sign that ever!

Mark Dice: No?

Man: Yeah!

Mark Dice: What's wrong with that?

(Men leave)

 

Mark Dice:  we figure

it's time to mandate that

any possible long-term side effects that

haven't been detected yet

we can maybe deal with that in the

future, Uh signature there as well (to woman signing the pettion) too, mandate,  mandate the vaccine

Man walking  by warns Dice he’s closer than 6 foot social distancing  limit (to woman signing). Man: “ You’re supposed to stay six feet away from everybody, Sir. You can't do that, Sir.”

Dice nods acknowledgement to him as woman walks away after signing.

Mark Dice: We hope to support the

mandatory vaccination program

a lot of people still refusing to get

vaccinated

 

Woman moves past, “Oh. No. Thank you.”

 

Mark Dice: (to man signing petition) drastic measures need to be taken these people can think about what they've done

when they're sitting in jail

Man: Right.

Mark Dice:  thank you

Mark Dice: (to two women)

and throw them in jail until the rest of

us, so the rest of us can be safe from them

not taking the coronavirus vaccine

 

Woman #1: Is that really what it’s about?

 

Mark Dice: Yeah (Woman #1 begins to sign petition)

it's the only way that we can protect

the rest of us. Just

Print, Birth Date and a Signature.

it's been long enough and we don't need

these people walking amongst us

 

One of the women says, “Right!”

 

Mark Dice: so we're gonna put them in jail if

they continue to refuse there will be a

30-day window where they can

go and get vaccinated before they're

arrested

 

Same woman again says “Right!

 

Mark Dice: but

until then we're going to we're going to

take care of them

 

Woman says, “Good! Yay!

 

Mark Dice:  thank you

 

Mark Dice: You don't want to help the program? (to two women) Why would you not want to tell ....

 

Woman (foreign accent): i think people can choice you know it's

up to them

 

Mark Dice: well we're going to help them

make that choice

and they need a little incentive to

sometimes people need incentives

 

Woman: Oh, Sir. I don’t think that way. 

 

Mark Dice: Oh you don't? okay well thank you

 

Mark Dice: (to another individual) well how

else are we going to get them away from us?

 

Woman (sternly): I’m sorry. Thank you (and walks away).

 

Mark Dice: Our governor just mandated vaccine for

all health care workers

but ordinary citizens can still refuse so

we're going to make them take that and

it's about time that things get back to

normal (to man signing the petition)

Don't you agree?

 

Man: Yep!


Mark Dice: Oh, Signature…

okay cool all right thank you very much

we're gonna

we'll have to decide for these people

what's best

Man: Yeah

Mark Dice: thank you

 

Mark Dice: (to woman walking by) Will you help us stop

these anti-vaxxers? the governor just

mandated the vaccine for health care

workers but

ordinary people are still refusing to

get vaccinated so we want to mandate it

for everybody

just to help make sure that we can get

back to normal


Woman: Do I need to be registered or anything?

 

Mark Dice: Nope. This isn't a this isn't nope this

isn't not even registered to vote at all

 

Woman: Okay. (begins to sign petition)

 

Mark Dice: Just the Name, Birth Date and a

Signature.

to mandate the vaccine even though this

is really the first

mrna vaccine and it's not fully approved

by the FDA


Woman (still signing): Right.

 

Mark Dice: We should still make these people take

it we'll decide for them what's best

all right thank you so much

 

Mark Dice: (to man walking dog) signatures here to start rounding up

these anti-vaxxers and have them

arrested if they continue to refuse the

vaccine,

okay?

 

Man: This is a joke , right?

Mark Dice: Oh it is a joke, actually. Yeah, okay.

yeah. Oh dude you'd be surprised how many people,

all these people signed (gesturing to collected signatures) and

agreed they want to arrest them

 

Man: Well, they are all idiots.

 

Mark Dice: They are all idiots. Well

thank you for not being one sir (shakes man’s hand)

appreciate that.

 

Conclusion of Mark Dice video shows

a black T-shirt with ARREST DR. FAUCI printed on it

(with a picture of the weasel).

The voiceover : Someone who should be

arrested however is dr

fauci and if you agree order my new

arrest dr fauci shirt

from my online store at markdice.com i

like all of my designs it's available in

a t-shirt long sleeve and a hoodie

and a whole bunch of different colors as

well so head on over to markdash.com or

click the link in the description below

and check it out

[Music]

2,188 posted on 09/10/2021 7:58:52 PM PDT by ransomnote (IN GOD WE TRUST)
[ Post Reply | Private Reply | To 2187 | View Replies]

To: ransomnote

My friend of forty years, who is no longer my friend, wants the unvaxed to be thrown out of ambulances and hospitals, let their lungs explode and die in the street.


2,189 posted on 09/10/2021 8:07:57 PM PDT by Toespi
[ Post Reply | Private Reply | To 2188 | View Replies]


Navigation: use the links below to view more comments.
first previous 1-20 ... 2,121-2,1402,141-2,1602,161-2,1802,181-2,189 last

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
General/Chat
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson